Suppressors of cytokine signaling (SOCS) negatively regulate the immune response, primarily by interfering with the JAK/STAT pathway. We have developed a small peptide corresponding to the kinase inhibitory region (KIR) sequence of SOCS-1, SOCS1-KIR, which inhibits kinase activity by binding to the activation loop of tyrosine kinases such as JAK2 and TYK2. Treatment of SJL/J mice with SOCS1-KIR beginning 12 days postimmunization with myelin basic protein (MBP) resulted in minimal symptoms of EAE, while most control treated mice developed paraplegia. SOCS1-KIR treatment suppressed interleukin-17A (IL-17A) production by MBP-specific lymphocytes, as well as MBP-induced lymphocyte proliferation. When treated with IL-23, a key cytokine in the terminal differentiation of IL-17-producing cells, MBP-sensitized cells produced IL-17A and IFNγ; SOCS1-KIR was able to inhibit the production of these cytokines. SOCS1-KIR also blocked IL-23 and IL-17A activation of STAT3. There is a deficiency of SOCS-1 and SOCS-3 mRNA expression in CD4 + T cells that infiltrate the CNS, reflecting a deficiency in regulation. Consistent with therapeutic efficacy, SOCS1-KIR reversed the cellular infiltration of the CNS that is associated with EAE. We have shown here that a SOCS-1 like effect can be obtained with a small functional region of the SOCS-1 protein that is easily produced.
Introduction
The immune system is remarkably complex and flexible, composed of innate and adaptive arms that allow rapid responses to a variety of threats to the individual. This system contains within itself regulators such as regulatory lymphocytes and suppressors of cytokine signaling (SOCS). These regulators are required in order to govern and limit the extent of the response of the effector arm of the immune system. An unregulated immune system quickly turns on the host and becomes a problem rather than a solution to threats on the individual.
Multiple sclerosis (MS) is a T cell-mediated autoimmune disease that targets the myelin sheath of neurons of the central nervous system (CNS) (Lassmann et al., 2007; Stuve, 2009) . It is a well-known example of dysregulation of the immune system where, for reasons not fully understood, the regulatory arms of the immune system fail in 250,000 to 400,000 Americans (Lassmann et al., 2007; Stuve, 2009) . It was widely felt that T-helper 1 (Th1) cells driven by the cytokine interleukin-12 (IL-12) were primarily responsible for the CNS pathology of MS with gamma interferon (IFNγ) as the effector cytokine (El Behi et al., 2010) . More recently, IL-17 producing CD4 + T cells (Th17 cells) have supplanted Th1 cells as the primary cause of MS (El Behi et al., 2005 , 2010 Korn et al., 2009; Boniface et al., 2008; Linker and Lee, 2009) . Experimental allergic encephalomyelitis (EAE) is a widely studied model of MS, with a view toward understanding the mechanism of disease, as well as therapeutic approaches to treatment (El Behi et al., 2005; Ercolini and Miller, 2006) . It is induced in mice, rats, and primates by immunization with proteins or peptides of the myelin sheath. We are particularly interested in manipulation of the SOCS arm of immune regulation as a therapeutic approach to the treatment of MS and EAE. SOCS are a family of eight proteins of which two, SOCS-1 and SOCS-3, are of interest to the natural regulation of the immune system with respect to MS and EAE and as targets of approaches to treating these diseases. SOCS-1 and SOCS-3 are structurally similar with, starting N-terminally, a 12-amino acid kinase inhibitory region (KIR), a large SH2 domain, and a 40-amino acid C-terminal SOCS box that is involved in proteasomal degradation of SOCS and its associated tyrosine kinases (Yasukawa et al., 1999; Alexander and Hilton, 2004; Yoshimura et al., 2007; Dalpke et al., 2008; Croker et al., 2008; Babon et al., 2009) . KIR and SH2 are involved in binding to tyrosine kinases with inhibition of catalytic activity (Babon et al., 2009; Croker et al., 2008; Waiboci et al., 2007) .
We have been interested in the interaction of SOCS-1 with the activation loop of the JAK2 tyrosine kinase. Accordingly, we designed a
